Final Scientific Programme - Wednesday

Wednesday, 14.9.2011

8.00-10.00 Main Hall (Aula Duza)

Oral presentations 10: Thyroid Cancer clinical (OP71-OP78)

Chair: Laurence Leenhardt (Paris, France); Marek Dedecjus (Lodz, Poland)

OP71  TI-RADS SCORE: CLINICAL EFFICIENCY EVALUATED WITH THE BETHESDA SYSTEM IN A ONE-YEAR PROSPECTIVE STUDY ON 2480 NODULES

Russ G¹, Bienvenu-Perrard M¹, Rouxel A¹, Royer B¹, Bigorgne C^1
1Centre de Pathologie et d'Imagerie, Paris, France

OP72  FOSBRETABULIN TROMETHAMINE (CA4P), A TUBULIN-BINDING VASCULAR DISRUPTING AGENT (VDA), IS ASSOCIATED WITH IMPROVED 1-YEAR SURVIVAL IN ANAPLASTIC THYROID CANCER (ATC) PATIENTS TREATED IN 5 INDEPENDENT PROSPECTIVE STUDIES COMPARED TO A LARGE SINGLE INSTITUTION HISTORICAL SERIES

Balkissoon J¹, Langecker P¹, Lu S-P¹, Remick S², Sosa JA³, Elisei R⁴, Mciver B⁵, Bal CS⁶, Gramza A⁷, Jarzab B⁸, Haugen B⁹, Gitlitz B¹⁰, Lu C¹¹, Marur S¹², Licitra L¹³, Ondrey F¹⁴, Karandikar SM¹⁵, Ben-Yosef R¹⁶, Khuri F¹⁷, Koussis H^18
1Oxigene, Oncology, South San Francisco, United States, ²West Virginia University, Medicine, Morgantown, United States, ³Yale University School of Medicine, Surgery, Division of Endocrine Surgery and Surgical Oncology, New Haven, United States, ⁴University of Pisa, Endocrinology, Pisa, Italy, ⁵Mayo Clinic, Endocrinology, Rochester, United States, ⁶AIIMS, Nuclear Medicine Therapy, New Dehli, India, ⁷National Cancer Institute, Head and Neck Oncology, Bethesda, United States, ⁸MSC Memorial Cancer Centre and Institute of Oncology, Gliwice, Poland, ⁹University of Colorado, Endocrinology, Aurora, United States, ¹⁰USC Norris Cancer Center, Los Angeles, United States, ¹¹MD Anderson Cancer Center, Houston, United States, ¹²Johns Hopkins University, Baltimore, United States, ¹³Istituto dei Tumori, Otolaryngology, Milano, Italy, ¹⁴University of Minnesota, Otolaryngology, Minneapolis, United States, ¹⁵Ruby Hall Clinic, Pune, Maharashtra, India, ¹⁶Tel Aviv Sourasky Medical Center, Head and Neck Oncology, Tel Aviv, Israel, ¹⁷Emory University, Atlanta, United States, ¹⁸Istituto Oncologico Veneto IRCCS, Padova, Italy

OP73  MIRNA EXPRESSION PATTERNS DIFFERENTIATE BETWEEN FOLLICULAR THYROID CARCINOMA (FTC) AND FOLLICULAR THYROID ADENOMA (FA)

Stokowy T^1,2, Wojtaś B¹, Fujarewicz K², Jarząb M¹, Pfeifer A¹, Jarząb B¹, Krogdahl A³, Hauptmann S⁴, Paschke R⁵, Eszlinger M^5
1Cancer Center and Institute of Oncology, Nuclear Medicine and Endocrine Oncology Department, Gliwice, Poland, ²Silesian University of Technology, Systems Engineering Group, Institute of Automatic Control, Gliwice, Poland, ³Odense University Hospital, Department of Pathology, Odense, Denmark, ⁴University of Halle, Institute for Pathology, Halle, Germany, ⁵University of Leipzig, Division of Endocrinology and Nephrology, Leipzig, Germany

OP74  COMPARISON OF FOUR STRATEGIES OF RADIOIODINE ABLATION: FINAL RESULTS OF THE RANDOMIZED, PROSPECTIVE ESTIMABL STUDY ON 752 LOW-RISK THYROID CANCER PATIENTS

Catargi B¹, Borget I², Deandris D², Zerdoud S³, Bridji B⁴, Bardet S⁵, Schvartz C⁶, Toubert M⁷, Bonichon F⁸, Benhamou E², Schlumberger M², ESTIMABL Study Group
¹Centre Hospitalier Universitaire, Bordeaux, France, ²Institut Gustave-Roussy, Villejuif, France, ³CLCC, Toulouse, France, ⁴CLCC, Nantes, France, ⁵CLCC, Caen, France, ⁶CLCC, Reims, France, ⁷APHP, Paris, France, ⁸Institut Bergonié, Bordeaux, France

OP75  HILO: MULTICENTRE RANDOMISED PHASE III CLINICAL TRIAL OF HIGH VS LOW DOSE RADIOIODINE, WITH OR WITHOUT RECOMBINANT HUMAN THYROID STIMULATING HORMONE (RHTSH), FOR REMNANT ABLATION FOR DIFFERENTIATED THYROID CANCER

Mallick U¹, Harmer C², Clarke S³, Moss L⁴, Nicol A⁵, Clarke P⁶, Smellie J⁷, McCready R⁸, Farnell K⁹, Franklyn J⁶, Nutting C¹⁰, Yap B¹¹, Lemon C¹², Wadlsey J¹³, Gerrard G¹⁴, Roques T¹⁵, Macias E¹⁶, Whitaker S¹⁷, Abdul-Hamid A¹⁸, Alvarez P¹⁹, Kadalayil L¹⁹, Hackshaw A^19
1Newcastle Hospitals NHS Trust, Northern Centre for Cancer Treatment, High Heaton, United Kingdom, ²formerly Royal Marsden Hospital, London, United Kingdom, ³Guys & St Thomas's Hospital, London, United Kingdom, ⁴Velindre Hospital, Cardiff, United Kingdom, ⁵Southern General Hospital,, Glasgow, United Kingdom, ⁶University of Birmingham, Birmingham, United Kingdom, ⁷Chelsea and Westminster Hospital, London, United Kingdom, ⁸Brighton and Sussex Medical School, Brighton, United Kingdom, ⁹Butterfly Cancer Trust UK, Newcastle, United Kingdom, ¹⁰Royal Marsden Hospital, London, United Kingdom, ¹¹Christie Hospital, Manchester, United Kingdom, ¹²Mount Vernon Hospital, Northwood, United Kingdom, ¹³Weston Park Hospital, Sheffield, United Kingdom, ¹⁴Cookridge Hospital, Leeds, United Kingdom, ¹⁵Norfolk & Norwich Univ Hospital NHS Trust, Norwich, United Kingdom, ¹⁶East Kent NHS Trust and Canterbury Hospital, Kent, United Kingdom, ¹⁷Royal Surrey County Hospital, Guildford, United Kingdom, ¹⁸Hull & East Yorkshire, Princess Royal Hospital, Hull, United Kingdom, ¹⁹University College London, London, United Kingdom

OP76  NOT ALL NEW RET MUTATIONS SHOW TRANSFORMING ACTIVITY WHEN ANALYZED BY IN SILICO AND IN VITRO ASSAYS

Elisei R¹, Cosci B¹, Vivaldi A¹, Romei C¹, Gemignani F², Landi S², Tacito A¹, Ciampi R¹, Bottici V¹, Cappagli V¹, Vitti P¹, Pinchera A^1
1University of Pisa, Department of Endocrinology, Pisa, Italy, ²University of Pisa, Department of Biology, Pisa, Italy

OP77  THYROID AUTOIMMUNITY AND THYROID CANCER: PATHOLOGICAL AND MOLECULAR STUDY IN A LONGITUDINAL SERIES OF UNSELECTED NODULES

Boi F¹, Caria P², Borghero A¹, Frau DV², Cappai A¹, Dettori T², Riola A¹, Maurelli I¹, Lai ML³, Calò PG⁴, Nicolosi A⁴, Vanni R², Mariotti S^1
1University of Cagliari, Department of Medical Sciences 'M. Aresu', Monserrato - Cagliari, Italy, ²University of Cagliari, Department of Biomedical Science and Technology, Monserrato - Cagliari, Italy, ³University of Cagliari, Department of Cytomorphology, Cagliari, Italy, ⁴University of Cagliari, Department of Surgical and Odontostomatological Sciences, Monserrato - Cagliari, Italy

OP78  CLINICAL SIGNIFICANCE OF ANTI-THYROID ANTIBODIES (AT-AB) TITER TREND IN A LONG-TERM FOLLOW-UP OF PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA (DTC)

Lorusso L¹, Agate L¹, Latrofa F¹, Bottici V¹, Molinaro E¹, Viola D¹, Grasso L¹, Pinchera A¹, Vitti P¹, Elisei R^1
1Department of Endocrinology, University of Pisa, Pisa, Italy

8.00‐10.00 Minor Hall

Oral presentations 11: Thyroid Hormone 2 (OP79-OP86)

Chair: Warner Simonides (Amsterdam, The Netherlands); Janusz K. Mysliwiec (Bialystok, Poland)

OP79  NOVEL TRANSGENIC TOOLS ILLUMINATE THE COORDINATED DEVELOPMENT OF THE THYROID GLAND AND THE CARDIOVASCULAR SYSTEM IN ZEBRAFISH EMBRYOS

Opitz R¹, Maquet E¹, Horicks F¹, Rodriguez W¹, Costagliola S^1
1ULB, IRIBHM, Brussels, Belgium

OP80 THE THYROID HORMONES INHIBIT TRANSCRIPTIONAL RESPONSES TO THE TRANSFORMING GROWTH FACTOR β

Ruiz-Llorente L¹, Martín-Orozco RM¹, Ardila S¹, Fanjul LF¹, Aranda A^1
1Inst. Investigaciones Biomedicas (IIB), CSIC-UAM, Madrid, Spain

OP81  EFFECTS OF MCT8 AND MCT10 ON THE BIOLOGICAL ACTIVITY OF T3

van Mullem AAA¹, Peeters RP¹, Visser TJ^1
1Erasmus MC, Internal Medicine, Rotterdam, Netherlands

OP82  TYPE 3 DEIODINASE IS HIGHLY EXPRESSED IN PROLIFERATING MYOBLASTS AND DURING THE EARLY PHASE OF MUSCLE REGENERATION

Dentice M¹, Luongo C¹, Ambrosio R¹, Sibilio A¹, Damiano V¹, De Stefano MA¹, Marsili A², Fenzi G¹, Larsen PR², Salvatore D^1
1Università degli studi di Napoli 'Federico II', Molecular and Clinical Endocrinology and Oncology, Naples, Italy, ²Brigham and Women's Hospital and Harvard Medical School, Thyroid Section, Division of Endocrinology, Diabetes and Hypertension, Boston, United States

OP83  TISSUE 3-IODOTHYRONAMINE UPTAKE IN VIVO: COMPARISON WITH EXPRESSION OF TRACE AMINE ASSOCIATED RECEPTORS

Frascarelli S¹, Chiellini G¹, Carnicelli V¹, Ghelardoni S¹, Erba P², Manfredi C², Mariani G², Zucchi R^1
1University of Pisa, Dip. di Scienze dell'Uomo e dell'Ambiente, Pisa, Italy, ²University of Pisa, Dip. di Oncologia, Pisa, Italy

OP84  UPTAKE AND METABOLIC EFFECTS OF 3-IODOTHYRONAMINE IN RAT LIVER

Ghelardoni S¹, Chiellini G¹, Frascarelli S¹, Marchini M¹, Saba A¹, Zucchi R^1
1University of Pisa, Dip. di Scienze dell'Uomo e dell'Ambiente, Pisa, Italy

OP85  THE ROLE OF MICRORNA AND PROMOTER METHYLATION IN REGULATION OF THYROID HORMONE RECEPTOR BETA EXPRESSION IN RENAL CANCER

Wojcicka A¹, Piekiełko-Witkowska A¹, Kedzierska H¹, Boguslawska J¹, Nauman A^1
1The Medical Centre of Postgraduate Education, Department of Biochemistry and Molecular Biology, Warsaw, Poland

OP86  DISTURBED ALTERNATIVE SPLICING OF TYPE 2 DEIODINASE IN PITUITARY TUMORS

Piekielko-Witkowska A¹, Kedzierska H¹, Wojcicka A¹, Grajkowska WA^2,3, Mandat T⁴, Matyja EM^2,4, Bonicki W⁴, Nauman P^5
1The Medical Centre of Postgraduate Education, Department of Biochemistry and Molecular Biology, Warsaw, Poland, ²M. Mossakowski Medical Research Centre, Polish Academy of Sciences, Department of Experimental and Clinical Neuropathology, Warsaw, Poland, ³The Children's Memorial Health Institute, Department of Pathology, Warsaw, Poland, ⁴M. Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Department of Neurosurgery, Warsaw, Poland, ⁵Institut of Psychiatry and Neurology, Department of Neurosurgery, Warsaw, Poland

10.00-10.15

Coffee Break

10.15-11.45 Minor Hall

Symposium 7 Basic: Thyroid hormone disrupters

Chair: Theo Visser (Rotterdam, The Netherlands); Barbara Czarnocka (Warsaw, Poland)

Thyroid hormone signalling in early development: a new window of vulnerability for endocrine disruption

 Barbara Demeneix (Paris, France)

Sunburn and thyroid dysfunction: the effect of UV blockers on the thyroid

Josef Köhrle (Berlin, Germany)

Putting out the thyroid with flame retardants: polybrominated compounds

Eddy Rijntjes  (Berlin, Germany)

10.15-11.45 Main Hall (Aula Duza)

Symposium 8 Clinical: Perspectives in the therapy of Graves’ disease

Chair: George J. Kahaly (Mainz, Germany); Tomasz Bednarczuk (Warsaw, Poland)

Unmet medical needs and therapeutic options in Graves’ disease                         

Luigi Bartalena (Varese, Italy)  

Selenium in Graves’ hyperthyroidism and orbitopathy                                                              

Claudio Marcocci (Pisa, Italy)

The CD-20-positive depleting agent, Rituximab                                                                           

Laszlo Hegedus (Odense, Denmark)

11.45 Closing Ceremony Main Hall (Aula Duza)

Presentation of:
Young Investigators Prize (clinical/basic) sponsored by Thermo Fisher Scientific
ETA Max Pierre Koenig Poster Prize (clinical) sponsored by the ETA
ETA Max Pierre Koenig Poster Prize (basic) sponsored by the ETA